Bilirubin Levels as Potential Indicators of Disease Severity in Coronavirus Disease Patients: A Retrospective Cohort Study
| Autor: | Guang Zeng, Danyang Chen, Xiaohui Wu, Zeming Liu, Liang Guo, Di Hu, Qianqian Li, Wei Long, Jinpeng Li, Shipei Wang, Wen Zeng, Rongfen Gao, Zhengwei Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty length of hospitalization Bilirubin Disease Logistic regression Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Interquartile range Internal medicine medicine 030212 general & internal medicine Original Research lcsh:R5-920 business.industry Proportional hazards model Hazard ratio COVID-19 Retrospective cohort study General Medicine Odds ratio mortality 030104 developmental biology chemistry Medicine disease severity bilirubin business lcsh:Medicine (General) |
| Zdroj: | Frontiers in Medicine, Vol 7 (2020) Frontiers in Medicine |
| Popis: | Objectives: The coronavirus disease (COVID-19) pandemic has caused a large number of deaths. Some patients with severe or critical COVID-19 have been observed to have elevated bilirubin levels. Studies on the association of bilirubin level and mortality in patients with COVID-19 are limited. This study aimed to examine the role of bilirubin levels in COVID-19 severity and mortality. Methods: A retrospective cohort study was conducted in patients hospitalized with COVID-19 in Leishenshan Hospital in Wuhan, China. Cox regression analyses and logistic regression analyses were conducted to investigate the risks for mortality and disease severity, respectively. Kaplan–Meier analyses with log-rank tests were performed to assess the association between bilirubin level and survival. Results: In total, 1,788 patients with COVID-19 were included in the analysis. 5.8% (4/69) of patients in the elevated serum total bilirubin (STB) group died, compared to 0.6% (11/1,719) of patients in the non-elevated STB group. The median alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities in the elevated STB group were 29 U/L [interquartile range (IQR): 16–45 U/L] and 22 U/L (IQR: 13–37 U /L), respectively, which were significantly higher than the median ALT (median: 23, IQR: 15–37) and AST (median: 20, IQR: 16–26) activities in the non-elevated STB group (both p < 0.05). Patients with an elevated STB level showed increased mortality [hazard ratio (HR): 9.45, P = 0.002], elevated conjugated bilirubin (CB) levels (HR: 4.38, P = 0.03), and an elevated ratio of CB to unconjugated bilirubin (UCB, CB/UCB) (HR: 2.49, P = 0.01). CB/UCB was positively correlated with disease severity (odds ratio: 2.21, P = 0.01). Conclusions: COVID-19 patients with elevated STB and CB levels had a higher mortality, and CB/UCB was predictive of disease severity and mortality. Thus, it is necessary to pay special attention to COVID-19 patients with elevated bilirubin levels in clinical management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|